Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05417165 · ClinicalTrials.gov registry record · Phase 2

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

A Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Seema Bhat.

Recruiting
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT05417165 is a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that is actively recruiting participants, run by Seema Bhat. The registered enrollment target is 80 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05417165, a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, is actively recruiting participants, sponsored by Seema Bhat.

RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose of PSV23 after an interval of two months, followed by revaccination at 5 years). Giving patients frequent immunization as compared to 5 year immunization may result in higher protective titers in patients.

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Interventions

  • BIOLOGICAL Pneumococcal 20-valent Conjugate Vaccine
  • BIOLOGICAL Pneumococcal Polyvalent Vaccine

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-09-29
Est. Completion 2026-10-31
Phase Phase 2

Sponsor

Seema Bhat

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05417165

The ClinicalTrials.gov registry entry for NCT05417165 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (56% lower). The listed sponsor is Seema Bhat, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Pneumococcal 20-valent Conjugate Vaccine is the first listed.

NCT05417165 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05417165 about?

NCT05417165 is a clinical study titled "Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia". This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vacc...

What is the current status of trial NCT05417165?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-09-29. Estimated completion is 2026-10-31.

What conditions does trial NCT05417165 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

What interventions are being tested in trial NCT05417165?

The interventions under investigation include: Pneumococcal 20-valent Conjugate Vaccine (BIOLOGICAL), Pneumococcal Polyvalent Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT05417165?

This trial is sponsored by Seema Bhat, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05417165 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Small Lymphocytic Lymphoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.